Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Fineline Cube Feb 12, 2026
Company Deals

Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs

Fineline Cube Feb 12, 2026
Company Deals

Jingxin Pharmaceutical Files Hong Kong IPO for Dual Listing Strategy

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Fineline Cube Feb 12, 2026
Company Drug

Henlius Biotech Initiates Phase Ib/II Study for HLX43 ADC Combinations in Colorectal Cancer

Fineline Cube Feb 12, 2026
Company Drug

Wuhan YZY Biopharma Gets FDA Nod for M701 Phase Ib/II MPE Study

Fineline Cube Feb 4, 2026

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) announced that the U.S. Food and Drug Administration...

Company

Amgen Q4 Revenue Grows 9% to $9.9B on Strong Product Sales

Fineline Cube Feb 4, 2026

Amgen (NASDAQ: AMGN) reported fourth‑quarter 2025 revenue of USD 9.9 billion, up 9% year‑over‑year (YOY), bringing full‑year revenue...

Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced plans to acquire 100% equity in Hebei Grand...

Company

Novo Nordisk Sales Reach DKK 309 Billion on GLP‑1 and Obesity Surge

Fineline Cube Feb 4, 2026

Novo Nordisk (NYSE: NVO) reported 2025 global sales of DKK 309 billion (USD 48.9 billion), representing 10% year‑on‑year (YOY) growth...

Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026

Simcere Pharmaceutical Group Ltd (HKG: 2096) announced it has received a USD 40 million near‑term milestone payment from...

Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026

Medtronic Inc. (NYSE: MDT) announced it will exercise its option to acquire Israel-based medical device company...

Company Deals

TenNor Therapeutics Files Hong Kong IPO for Anti-Infective Pipeline

Fineline Cube Feb 4, 2026

TenNor Therapeutics (Suzhou) Limited submitted its initial public offering (IPO) application to the Main Board...

Company Drug

BeBetter Med BEBT-701 Approved for Hypertension siRNA Trial

Fineline Cube Feb 4, 2026

Guangzhou BeBetter Medicine Technology Co., Ltd. (SHA: 688759) announced that the National Medical Products Administration...

Company Drug

AbbVie Files Rinvoq for Vitiligo Approval in US and EU

Fineline Cube Feb 4, 2026

AbbVie (NYSE: ABBV) announced it has submitted new indication applications to the U.S. Food and Drug...

Company Drug

Datroway TNBC sBLA Gets FDA Priority Review for Triple-Negative Breast Cancer

Fineline Cube Feb 4, 2026

AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that the U.S. Food and Drug Administration...

Company Drug

Bayer Nubeqa Gets NMPA Approval for Metastatic Prostate Cancer

Fineline Cube Feb 4, 2026

Bayer AG (ETR: BAYN) announced that the National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide)...

Company

Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data

Fineline Cube Feb 4, 2026

Daiichi Sankyo (TYO: 4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting...

Company Deals

Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone

Fineline Cube Feb 3, 2026

Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study...

Company Deals

PrimeGenX Therapeutics Files Hong Kong IPO for Pumecitinib Platform

Fineline Cube Feb 3, 2026

PrimeGenX Therapeutics Co., Ltd., a Beijing‑based immuno‑inflammation biotech founded in 2016, made an initial public...

Company Medical Device

Hengrui Resubmits Camrelizumab-Apatinib BLA for HCC to FDA

Fineline Cube Feb 3, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the U.S. Food and Drug Administration...

Company Deals

Jumpcan Licenses PrimeGenX Pumecitinib Nasal Spray for Allergic Rhinitis

Fineline Cube Feb 3, 2026

Jumpcan Pharmaceutical (SHA: 600566) announced a partnership with PrimeGenX Therapeutics Co., Ltd. granting Jumpcan exclusive...

Company Medical Device

ZEISS ARTEVO Gets NMPA Approval for China Ophthalmology Market

Fineline Cube Feb 3, 2026

ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) has approved the ARTEVO...

Company Drug

Venglustat Gaucher: Sanofi Meets Primary Endpoint in Phase 3 LEAP2MONO Study

Fineline Cube Feb 3, 2026

Sanofi (NASDAQ: SNY) announced positive results from the LEAP2MONO phase 3 study (NCT05222906), showing venglustat met the...

Company Deals

Arctic Vision-Mdco Technology Merger Builds Ophthalmology Platform

Fineline Cube Feb 3, 2026

Arctic Vision, a China‑based ophthalmology specialist, and Mdco Technology Co., Ltd. have agreed to integrate...

Company

Eli Lilly to Invest $3.5B in Pennsylvania Plant for Retatrutide Production

Fineline Cube Feb 3, 2026

Eli Lilly (NYSE: LLY) announced plans to invest more than USD 3.5 billion in a new manufacturing facility...

Posts pagination

1 … 5 6 7 … 624

Recent updates

  • Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals
  • Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
  • Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials
  • MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer
  • Sanofi Invests $30 Million in GluBio’s Sickle Cell TPD Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Company Deals

Therom Fisher’s PPD Partners with Datavant to Integrate Real-World Data into Clinical Trials

Company Drug

MSD’s Keytruda Wins FDA Approval for Platinum-Resistant Ovarian Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.